Application of Human Leucocyte Interferon in Patients With Urinary Bladder Papillomatosis, Breast Cancer, and Melanoma

Ikíc, D.; Maricić, Z; Orešić, V.; Rode, Bojan; Nola, P; Smudj, K.; Knezević, M; Jusić, D; Sooś, E

doi:10.1016/s0140-6736(81)92188-7

Cited by 29 publications

(13 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The good results reported earlier [1][2][3] were not confirmed in a recently published study by the authors of this study [4].…”

Section: Introductioncontrasting

confidence: 93%

“…The natural IFN-p prepa rations used had stronger antiproliferative effects as compared to the effects of IFN-d2C . These data could be helpful in understanding the controversial results pub lished in previous clinical trials in which superficial bladder tumors were treated by IFN [1][2][3][4], The natural IFN preparation used in some of these studies contained undefined mixtures of different IFN classes and differ ent IFN subtypes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Antiproliferative Effects of Interferons against Human Bladder Carcinoma Cell Lines in vitro

Grups

Frohmüller²

1988

Urol Int

View full text Add to dashboard Cite

In order to evaluate the antiproliferative effects of recombinant human interferon-Γ_2c (rHu IFN-Γ_2c), recombinant human interferon-Γ (rHu IFN-Γ), natural interferon-Β (IFN-Β), and their combination with cytotoxic agents, 17 different human bladder carcinoma cell lines were tested in vitro. The antiproliferative effects were compared in evaluating the tumor cell inhibiting potency of the different interferon (IFN) classes. It could be demonstrated that interferons have inhibiting effects on the bladder cancer cell multiplication rate, yet there are significant differences in the susceptibility of different IFN preparations on different cell lines. The cell lines BT1, RT4, EJ, 468P, 253J, SD, TCCSUP, and SW1738 can be defined as sensitive, T24, 647V, VM-CUB2, and J82 as semisensitive, HT1376, 5637, VM-CUB1, 639V and SW1710 as resistant upon treatment with IFN. The combination of rHu IFN-Α_2c, IFN-Β, and rHu IFN-Γ seems to be more effective than treatment with rHu IFN-Α_2c alone. The cytotoxic effect of doxorubicin on bladder cancer cells can be intensified by combining it with IFN.

show abstract

“…The good results reported earlier [1][2][3] were not confirmed in a recently published study by the authors of this study [4].…”

Section: Introductioncontrasting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Antiproliferative Effects of Interferons against Human Bladder Carcinoma Cell Lines in vitro

Grups

Frohmüller²

1988

Urol Int

View full text Add to dashboard Cite

show abstract

“…Ikic et al [5] used crude human leukocyte IFN to treat recurrent malignant papil lomatosis of the urinary bladder in 8 patients who had been treated with transurethral resection (TUR) and coag ulations. For 21 days each month until the tumor re gressed, patients received 2 million units (MU) intravesically.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Two Doses of lnterferon-Alpha-2b in Intravesical Prophylaxis of Superficial Bladder Tumors

Silva¹,

Furtado²,

Reis³

et al. 1995

Eur Urol

View full text Add to dashboard Cite

“…Ikic et al [3] reported 5 complete responses (CRs) in 8 patients suffer ing from superficial bladder tumors with repeated intra tumoral injections of leucocyte interferon. Torti et al [4] observed 6 CRs in 8 carcinoma in situ but 0 CR in 8 papillary tumors with repeated intravesical instillations of alpha-2-interferon at various dosages.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Superficial Bladder Tumors with Intravesical Recombinant Interferon Alpha-2a

et al. 1988

View full text Add to dashboard Cite

In a prospective study, the toxicity and efficacy of an instillation therapy with recombinant interferon alpha-2a (rIFN-α-2a) were evaluated in 12 patients with superficial bladder tumors. Treatment consisted of 8 weekly instillations of 54 × 10⁶ IU rIFN-α-2a in 50 ml saline. Two weeks after completion of the instillation therapy, the tumor status was assessed with cystoscopy, biopsy and bladder wash-out cytology. Two partial responses, 1 no change and 2 progressive disease were seen in the 5 patients with TA tumors. In the 4 patients with carcinoma in situ, 1 complete response, 1 partial response and 2 no change were observed. Three patients suffered from carcinoma in situ and superficial papillary tumors, 1 showed complete response of the carcinoma in situ but no change of the TA tumor, the other 2 patients showed progressive disease. Three patients with partial response received a follow-up combination therapy with interferon intravesically and etretinate orally (25 mg/day). These patients presented progressive disease or no change 10 weeks after starting the follow-up combination therapy. During the treatment period, no side effects of interferon or changes of the serum interferon levels were observed. The treatment results are considered unsatisfactory; nevertheless, some activity after intravesical administration of interferon (mainly in patients with carcinoma in situ) could be demonstrated. Since the cytotoxic and antiproliferative effects seem to be dose-dependent, further studies might be done using higher interferon dosages and shorter treatment intervals.

show abstract

Application of Human Leucocyte Interferon in Patients With Urinary Bladder Papillomatosis, Breast Cancer, and Melanoma

Cited by 29 publications

References 1 publication

Antiproliferative Effects of Interferons against Human Bladder Carcinoma Cell Lines in vitro

Antiproliferative Effects of Interferons against Human Bladder Carcinoma Cell Lines in vitro

Comparison of Two Doses of lnterferon-Alpha-2b in Intravesical Prophylaxis of Superficial Bladder Tumors

Treatment of Superficial Bladder Tumors with Intravesical Recombinant Interferon Alpha-2a

Contact Info

Product

Resources

About